Company news
Atara Biotherapeutics, Inc. news in 2025
Atara Biotherapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
November 12, 2025
Atara Biotherapeutics Announces Changes to Its Board of Directors
September 3, 2025
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
August 11, 2025
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
July 24, 2025
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
July 14, 2025
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
May 16, 2025
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
May 15, 2025
Atara Biotherapeutics Announces Pricing of $16 Million Offering
May 15, 2025
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
May 5, 2025
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
March 7, 2025
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
January 20, 2025
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
January 15, 2025